Drugs Made In America Acquisition (DMIIR) Accounts Payables (2025)

Drugs Made In America Acquisition's (DMIIR) quarterly Accounts Payables came in at $99359.0 in Q4 2025, up 2063.74% on a QoQ basis from $4592.0 in Q3 2025.

Drugs Made In America Acquisition (DMIIR) Accounts Payables (2025) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has 1 years of Accounts Payables data on file, last reported at $99359.0 in Q4 2025.

  • On a quarterly basis, Accounts Payables changed N/A year-over-year to $99359.0 in Q4 2025; TTM through Dec 2025 was $99359.0, a N/A change from a year earlier, with the FY2025 full-year figure at $99359.0, changed N/A from the prior year.
  • Accounts Payables for Q4 2025 stood at $99359.0, up from $4592.0 in the prior quarter.
  • Over the last five years, Accounts Payables for DMIIR reached as high as $99359.0 in Q4 2025 and fell as low as $4592.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Accounts Payables (Qtr)
1 EQV Ventures Acquisition 480.75 Mn 480.75 Mn - -
2 Agriculture & Natural Solutions Acquisition 393.29 Mn 393.29 Mn - 56,828.00
3 Berto Acquisition 314.56 Mn 314.35 Mn - 167,813.00
4 GP-Act III Acquisition 313.66 Mn 313.66 Mn - -
5 Centurion Acquisition 311.65 Mn 311.65 Mn - 144,789.00
6 Republic Digital Acquisition 310.50 Mn 309.63 Mn - 38,697.00
7 Siddhi Acquisition Corp (Cayman Islands) 288.97 Mn 288.97 Mn - -
8 K&F Growth Acquisition 283.42 Mn 283.42 Mn - -
9 Bold Eagle Acquisition 275.29 Mn 275.29 Mn - 30,671.00
10 Drugs Made In America Acquisition - - - 99,359.00

Historic Data

Download Data
DateValue
Dec 31, 2025 99,359.00
Sep 30, 2025 4,592.00